多只港股通ETF提示溢价风险；葛兰、傅鹏博、萧楠最新调仓动作曝光

Group 1 - Jianxin Fund plans to invest at least 180 million yuan in its equity public products, having already invested 173 million yuan from Q4 2024 to Q1 2025 [1] - Multiple Hong Kong Stock Connect ETFs have issued warnings about premium risks due to high trading activity during the market closure, with some ETFs experiencing daily turnover rates exceeding 900% [1] - QDII funds have significantly reduced their holdings in US stocks, reallocating to A-shares and Hong Kong stocks [1] Group 2 - Fund manager Ge Lan has reduced her stake in Xinlitai by 2.1673 million shares, as reported in the company's Q1 2025 report [2] - Fund manager Fu Pengbo has slightly increased his position in Furuide by 120,000 shares, according to the latest Q1 2025 report [2] - Fund manager Xiao Nan has increased the allocation to liquor stocks, viewing it as a high-yield bond with domestic demand upside [3] Group 3 - The market showed mixed performance with the Shanghai Composite Index up 0.25% and the Shenzhen Component down 0.36%, with a total trading volume of 1.09 trillion yuan [4] - Hong Kong innovative drug-related ETFs saw strong performance, with some rising by as much as 5.77% [4][5] - A report indicates that the pharmaceutical sector may attract market funds due to previous declines, with investment opportunities focusing on innovative and generic drugs, as well as medical devices and services [7] Group 4 - A new fund, the China Securities Index Free Cash Flow ETF, is set to launch, managed by Xu Rongman, with a performance benchmark based on the China Securities Index Free Cash Flow Index [8]